Conditions: Non-Hodgkin's Lymphoma
Keywords: Bortezomib Bendamustine Rituximab Relapsed Refractory Mantle Cell Indolent
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 31
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.

Detailed description:

Arms:
arm 1: Subjects that met all eligibility criteria and were treated with Bendamustine, Rituxan and Bortezomib.

Interventions: intervention 1: bortezomib intervention 2: bendamustine intervention 3: rituximab
Intervention descriptions: intervention 1: 1.3 mg/m\^2 on days 1, 4, 8, 11 intervention 2: 90 mg/m\^2 days 1 and 4 intervention 3: 375 mg/m\^2 day 1

Protocol document: